Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Immunic (IMUX) announced the pricing of a registered direct offering of 5,666,667 shares of its common stock at a price of 90c per share, led ...

Immunic ( ($IMUX) ) has shared an announcement. On April 9, 2025, Immunic, Inc. announced a securities purchase agreement with institutional and ...

Fintel reports that on March 25, 2025, William Blair initiated coverage of Immunic (NasdaqGS:IMUX) with a Outperform ...

Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today ...

Immunic, Inc. (NASDAQ:IMUX – Get Free Report) has received a consensus rating of “Buy” from the nine brokerages that are ...

Immunic (NASDAQ:IMUX – Get Free Report) is anticipated to announce its earnings results before the market opens on Thursday, March 13th.Analysts expect the company to announce earnings of ($0.24 ...

Immunic, Inc. Announces Closing of $5.1 Million Registered Direct Offering, Led by Aberdeen Investments ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...

Immunic, Inc. ("Immunic" or the "Company") (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...